Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Deferred Revenue: 2020-2024

Historic Current Deferred Revenue for Caribou Biosciences (CRBU) over the last 5 years, with Dec 2024 value amounting to $6.4 million.

  • Caribou Biosciences' Current Deferred Revenue fell 41.37% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 41.37%. This contributed to the annual value of $6.4 million for FY2024, which is 27.97% down from last year.
  • According to the latest figures from FY2024, Caribou Biosciences' Current Deferred Revenue is $6.4 million, which was down 27.97% from $8.9 million recorded in FY2023.
  • Caribou Biosciences' 5-year Current Deferred Revenue high stood at $30.7 million for FY2021, and its period low was $161,000 during FY2020.
  • Moreover, its 3-year median value for Current Deferred Revenue was $8.9 million (2023), whereas its average is $13.8 million.
  • Per our database at Business Quant, Caribou Biosciences' Current Deferred Revenue spiked by 18,990.06% in 2021 and then crashed by 65.44% in 2023.
  • Over the past 5 years, Caribou Biosciences' Current Deferred Revenue (Yearly) stood at $161,000 in 2020, then spiked by 18,990.06% to $30.7 million in 2021, then fell by 15.76% to $25.9 million in 2022, then tumbled by 65.44% to $8.9 million in 2023, then dropped by 27.97% to $6.4 million in 2024.